This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Fatouros, M. Articles by Roukos, D. H. Search for Related Content PubMed PubMed Citation Articles by Fatouros, M. Articles by Roukos, D. H.

The Predominant Role of Surgery in the Prevention and New Trends in the Surgical Treatment of Women With BRCA1/2 Mutations

Department of Surgery, Ioannina University School of Medicine, 45110, Ioannina, Greece

Correspondence: Address correspondence and reprint requests to: Dimitrios H. Roukos, MD; E-mail: droukos{at}cc.uoi.gr

Background: Advances in understanding molecular and genetic mechanisms underlying cancer promise an "individualized" management of the disease. Women with a BRCA1 or BRCA2 germ-line mutation are at very high risk of breast and/or ovarian cancer. Because high-quality data are lacking from randomized trials, prevention strategies and treatment of patients with BRCA-associated breast cancer are complex.

Methods: The data for this review were obtained by searching PubMed and Medline for articles about optimizing prevention and treating women with familial susceptibility to breast and ovarian cancer.

Results: Prophylactic surgery is the rational approach for women who carry the BRCA mutation; chemoprevention and/or intensified surveillance represent alternative approaches. Prophylactic bilateral salpingo-oophorectomy is superior to bilateral prophylactic mastectomy. However, reaching a definitive clinical decision is complex, and several variables should be considered for an individualized approach. Accumulating data support the concept of more extensive surgery for newly diagnosed breast cancer in women with a BRCA mutation but new unbaised studies are needed for an evidence-based approach . Such patients treated with breast conservation therapy for early-stage breast cancer are at higher risk of contralateral breast cancer than noncarriers. Primary bilateral mastectomy could also be considered and discussed with these patients. Breast tumors from BRCA1 mutation carriers are predominantly of basal subtype (i.e., triple negative), and BRCA2 mutation carriers are of luminal subtype (i.e., estrogen receptor positive). Decisions on adjuvant treatment are based on estrogen receptor, progesterone receptor, and HER2 status.

Conclusions: The complex management of healthy women and breast cancer patients with familial susceptibility to breast and ovarian cancer requires an individualized prevention or treatment strategy by an experienced team.

Key Words: BRCA • Hereditary breast ovarian cancer • Prophylactic surgery • Chemoprevention • Screening • Treatment

This article has been cited by other articles:

				G. Zografos and D. H. Roukos International Randomized Trials' Attention to Locoregional Breast Cancer Control and Promise of Personal Genomics and Whole-Genome Scans for Personalized Approaches Ann. Surg. Oncol., January 1, 2009; 16(1): 222 - 225. [Full Text] [PDF]

				E. Fatourou, A. Macheras, E. P. Misiakos, and T. Liakakos Perioperative Chemotherapy for Gastric Cancer Ann. Surg. Oncol., January 1, 2009; 16(1): 226 - 227. [Full Text] [PDF]

				D. Ziogas, E. Ignatiadou, D. Roukos, and E. Lykoudis HER2 and Trastuzumab: Impact of a New Standard Agent on Local Control and Surgery for Breast Cancer Ann. Surg. Oncol., December 1, 2008; 15(12): 3614 - 3615. [Full Text] [PDF]

				E. Ignatiadou, D. Ziogas, E. Lykoudis, E. P. Misiakos, and T. Liakakos Screening for or Prevention of Local Ipsilateral Recurrence and Contralateral Breast Cancer After Breast-Conserving Surgery? Ann. Surg. Oncol., December 1, 2008; 15(12): 3617 - 3619. [Full Text] [PDF]

				T. Liakakos Benefits and Harms in Avoiding Axilla Lymphadenectomy in Breast Cancer Ann. Surg. Oncol., October 1, 2008; 15(10): 2978 - 2979. [Full Text] [PDF]

				T. Liakakos, E. Fatourou, D. Ziogas, E. Lykoudis, and D. H. Roukos Targeting VEGF, EGFR, and Other Interacting Pathways for Gastric Cancer--Promises and Reality Ann. Surg. Oncol., October 1, 2008; 15(10): 2981 - 2982. [Full Text] [PDF]

				T. Liakakos and E. Fatourou Stage-Specific Guided Adjuvant Treatment for Gastric Cancer Ann. Surg. Oncol., September 1, 2008; 15(9): 2622 - 2623. [Full Text] [PDF]

				D. Ziogas and T. Liakakos Lessons from Laparoscopic Gastrectomy: Preventing Surgical Complications Ann. Surg. Oncol., September 1, 2008; 15(9): 2624 - 2625. [Full Text] [PDF]

				D. Ziogas, P. Tsekeris, and E. Fatourou Benefits, Limitations, and Harm of Local Excision for Rectal Cancer Ann. Surg. Oncol., September 1, 2008; 15(9): 2628 - 2629. [Full Text] [PDF]

				D. Ziogas, E. Ignatiadou, and M. Fatouros Lumpectomy and Partial Breast Irradiation - Risks and Benefits for Early Breast Cancer Ann. Surg. Oncol., August 1, 2008; 15(8): 2352 - 2353. [Full Text] [PDF]

				T. Liakakos Minimal Residual Disease in Breast Cancer: Can It Be Used as a Prognostic Marker? Ann. Surg. Oncol., June 1, 2008; 15(6): 1793 - 1794. [Full Text] [PDF]

				E. Briasoulis and D. H. Roukos Contralateral Prophylactic Mastectomy: Mind the Genetics J. Clin. Oncol., April 10, 2008; 26(11): 1909 - 1910. [Full Text] [PDF]

				H. Harissis and M. Fatouros Nodal Micrometastases Status--Will It Influence Decisions on Surgical and Adjuvant Treatment for Breast Cancer? Ann. Surg. Oncol., April 1, 2008; 15(4): 1256 - 1257. [Full Text] [PDF]